List view / Grid view

Drug Discovery

 

article

How will MicroRNAs affect the drug discovery landscape?

21 July 2007 | By Dr. Neil Clarke and Dr. Mark Edbrooke, GlaxoSmithKline Research and Development, Hertfordshire, UK

The archetypal microRNAs, lin-4 and let-7, were discovered in the nematode worm Caenorhabditis elegans over a decade ago and, at that time, no one would have predicted that they would be anything other than an interesting feature of worm developmental biology. However, in recent years there has been an explosion…

article

The impact of automation on drug discovery

21 July 2007 | By William P. Janzen, President and COO, Amphora Discovery

Automated systems and modern pharmaceuticals have both had a hugely positive impact on human life. While these technologies developed in parallel with one another during roughly the same time period in the early 20th century, they didn’t interact until automation found its way into the laboratory in the 1970s.

article

Merck & Co.’s automated compound distribution centre

23 May 2006 | By Collette S. DeChard, Manager Compound Management Group, Fredric J. Solomon, Senior Automation Project Engineer, Robert Donnenberg Lead Application Services, Merck & Co., Inc.

In the mid-1990s, HTS labs were equipped with high-end automation for screening tens of thousands of compounds while compound management labs continued to manually pick samples and invest in standalone equipment...

article

The AstraZeneca ACMF

22 August 2005 | By Dr Dalin Nie, Associate Director, and Deborah S. Hartman, Director, Lead Discovery, AstraZeneca Pharmaceuticals, Wilmington

Compound management is an emerging discipline that represents a core component of the drug discovery process, from early phases involving high throughput screening (HTS) to late-stage lead optimisation screening cascades.